Company Northwest Biotherapeutics, Inc. Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Market Closed - Börse Stuttgart Other stock markets 15:55:45 2026-08-11 EDT			5-day change	1st Jan Change
0.1800 ^EUR	0.00%		+36.36%	-12.62%

08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI

Business description: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Number of employees: 105

Sales by Activity: Northwest Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Discover and Develop Innovative Immunotherapies for Cancer	1M	1.68M	1.93M	1.38M	1.38M

See all business segments

Geographical breakdown of sales: Northwest Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	1M	1.68M	1.93M	1.38M	1.38M

See all geographic segments

Executive Committee: Northwest Biotherapeutics, Inc.

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31
David Innes IRC	Investor Relations Contact	-	2019-02-25

See NORTHWEST BIOTHERAPEUTICS, INC. governance

Composition of the Board of Directors: Northwest Biotherapeutics, Inc.

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31
Joseph Black BRD	Director/Board Member	76	2016-01-26
Pat Sarma BRD	Director/Board Member	81	2024-03-17

Composition of the Board of Directors

Shareholders: Northwest Biotherapeutics, Inc.

Name	Stocks	%	Valuation
Linda Powers 1.742 %	29,411,759	1.742 %	5 M €
Pat Sarma 0.4363 %	7,365,069	0.4363 %	1 M €
Kelleher Financial Advisors LLC 0.0474 %	800,000	0.0474 %	131 200 €
Moloney Securities Asset Management LLC 0.0317 %	534,710	0.0317 %	87 692 €
Marnix Bosch 0.007651 %	129,157	0.007651 %	21 182 €

Name	Stocks	%	Valuation
Jerry Jasinowski 1.882 %	28,235	1.882 %	4 631 €

List of NORTHWEST BIOTHERAPEUTICS, INC. shareholders

Company details: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane

20814, Bethesda

+240 497 9024

http://www.nwbio.com

address Northwest Biotherapeutics, Inc.(NBYB)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.70%	+13.34%	+75.61%	+103.83%	70.85B
ARGENX SE	-2.35%	+3.71%	+31.77%	+63.89%	55.41B
INSMED INCORPORATED	-1.62%	+34.25%	+17.43%	+491.04%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	-0.30%	+18.51%	+56.61%	+4.86%	24.12B
BIONTECH SE	0.00%	+1.59%	-15.06%	-13.21%	23.31B
GENMAB A/S	+0.05%	+7.96%	+44.21%	-22.57%	18.37B
PHARMAESSENTIA CORPORATION	+9.77%	+20.16%	+260.17%	+472.38%	16.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+10.84%	+31.14%	+628.97%	16.1B
EXELIXIS, INC.	-3.08%	-8.34%	+37.21%	+138.52%	13.12B
Average	+0.20%	+391.85%	+59.90%	+207.52%	29.75B
Weighted average by Cap.	-0.40%	+350.76%	+55.54%	+167.02%